All Type of News
Baraclude generics land large hospitals in series
As a series of Baraclude generics have landed in large hospitals, they have started to create competitions against the original product.
According to the industry concerned on the 14th, Asan Medical Center has recen...
1 of 4 listed pharmaceutical companies have ‘unsound’ financial structures
1 of 4 listed pharmaceutical companies were indicated to have poor financial status with over 100% debt ratios.
In addition, Myungmoon Pharm and JW Shinyak exceeded 200% in the ratio while Sama Pharm was observed to ...
“Lenvima suggests a new option for radioiodine-refractory thyroid cancer”
A new treatment option was added in the radioiodine-refractory local recurrent or progressive differentiated thyroid cancer treatment.
Eisai Korea(CEO Hong-byung Goh) held a press conference to celebrate the launch ...
“Biosimilar prices should be accepted at 80% of the original prices”
A business conference for the biopharmaceutical drug pricing system opened. While relative issues were focused into 3 items, serious conversations were shared even on the first day, which means it was hard to find agr...
Cold patients spend annually KRW 81 thousand per person
It was analyzed patients receiving the National Health Insurance benefits for treating ‘acute upper respiratory infections(J00-J06),’ also known as cold, are mainly distributed from March to April.
Its medical expen...
Unstoppable listed pharmaceutical companies in 2015, solidifying both internally and externally
In 2015, listed pharmaceutical companies were observed to bear satisfactory fruits both internally and externally. Particularly, their sales growth rate went over double of their profit growth rate.
According to the ...
Biopharmaceutical investment only reaching 1/10 of other competing countries
After the Korea Exchange created the ‘Exceptional Listing Clause through Technology Evaluation’ on December 2005, the total 27 biotechnology companies have acquired approval to go public through it until the end of 20...
‘Domestic drug invigoration campaign’ will be conducted even stronger
Campaigns to invigorate domestic drugs developed by domestic pharmaceutical companies are getting more intense.
According to the distribution industry, the pharmaceutical distribution industry across the nation is g...
Selective intensive evaluation reduces KRW 113.4 billion medical expenses last year
The Health Insurance Review & Assessment Service(Chief Director Myung-sae Sohn, hereinafter referring to HIRA) announced a KRW 113.4 billion reduction in the national medical expenses and improvement of treatment type...
Evolution of domestic botulinum by Nabota, Botulax and Innotox
Development of domestically-developed botulinum toxin products has drawn attention. As amazingly securing 10 indications, they have challenged to the stronghold of Allergan’s Botox that is sold in 75 different countri...
